Company Arrowhead Research Corp Nasdaq
Equities
US0427972098
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Drugs
100.0
%
| 243 | 100.0 % | 241 | 100.0 % | -1.03% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 243 | 100.0 % | 241 | 100.0 % | -1.03% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 30/11/07 | |
Director of Finance/CFO | 57 | 31/12/08 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/22 |
Patrick O'brien
CMP | Compliance Officer | 60 | 30/11/14 |
Bruce Given
COO | Chief Operating Officer | 69 | 25/10/11 |
Vincent Anzalone
IRC | Investor Relations Contact | - | - |
Aaron Tan
AUD | Comptroller/Controller/Auditor | - | 30/06/21 |
Nadia Meshkova
TRE | Treasurer | - | - |
Tracie Oliver
PRN | Corporate Officer/Principal | 62 | 31/05/22 |
Matt Pulisic
PRN | Corporate Officer/Principal | - | 31/07/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 22/11/10 |
Michael Perry
BRD | Director/Board Member | 64 | 18/12/11 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 31/08/20 |
Hong Bo Lu
BRD | Director/Board Member | 53 | 03-31 |
Chief Executive Officer | 54 | 30/11/07 | |
William Waddill
BRD | Director/Board Member | 67 | 31/12/17 |
Mauro Ferrari
BRD | Director/Board Member | 64 | 18/08/10 |
Director/Board Member | 60 | 01/05/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 124,200,230 | 118,638,599 ( 95.52 %) | 0 | 95.52 % |
Company contact information
Arrowhead Pharmaceuticals, Inc.
177 East Colorado Boulevard Suite 700
91105, Pasadena
+626 304 3400
http://www.arrowheadpharma.comSector
1st Jan change | Capi. | |
---|---|---|
+10.42% | 114B | |
+13.06% | 107B | |
-5.51% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.61% | 17.51B | |
-39.36% | 17.17B | |
+7.45% | 14.14B | |
+34.93% | 12.2B |